title: Cell based therapies in Parkinson's Disease.
abstract: Parkinson's disease (PD) is the second most common neurodegenerative disorder after Alzheimer's disease. It is characterized by bradykinesia, hypokinesia/ akinesia, rigidity, tremor, and postural instability, caused by dopaminergic (DA) striatal denervation. The prevalence of PD increases from 50 years of age with steep rise after age 60 years. Current treatment of PD relies heavily on replacing lost dopamine either with its precursor L-dopa or dopamine agonists (ropinirole, pramipexole, bromocriptine, lisuride etc). Other pharmacological measures like catechol-O-methyltrasferase (COMT) inhibitors like entacopone, telcapone and monoamine oxidase B (MAO-B) inhibitors like selegiline and rasagiline are also useful, while L-dopa remains the gold standard in the treatment of PD. Emerging therapies are focusing on cell based therapeutics derived from various sources.
authors.affiliation: Department of Neurology, All India Institute of Medical Sciences, New Delhi 110057, INDIA.
authors.forename: Madhuri
authors.initials: M
authors.lastname: Behari
authors.affiliation: Department of Neurology, All India Institute of Medical Sciences, New Delhi 110057, INDIA.
authors.forename: Kapil Kumar
authors.initials: KK
authors.lastname: Singhal
keywords: Cell Based Therapy; PD Treatment; Parkinson’s Disease, Stem Cells